Healthcare Sales & Marketing Network News: trastuzumab emtansine

Searching News Database: trastuzumab emtansine

HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Nov 2013
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
Biopharmaceuticals Drug Delivery Oncology Regulatory

HSMN NewsFeed - 26 Nov 2012
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Oct 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Mar 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jan 2012
ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
Biopharmaceuticals Oncology Personnel

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.